Misdirected Congressional Fears Over Avandia Risk Coverup?

Trevor Butterworth
On October 18, The European Medicines Agency announced (pdf) that “having assessed all the data,” the benefits of the antidiabetic medicine Avandia (along with rival Actos) outweighed the risks. The Agency added:

“However, the prescribing information should be updated to include a warning that, in patients with ischaemic heart disease, rosiglitazone [Avandia] should only be [...]

The Cost of Media Scare Stories to Diabetics

Trevor Butterworth
The current issue of Biocentury, a trade publication that covers the pharmaceutical industry, should be essential and chastening reading for the journalists, editors and politicians who helped turn a limited, problematic study on the risks of the diabetes drug rosliglitazone (brand name Avandia) into a major international health scare.
In a comprehensive report on the [...]

So What Did We Learn From Avandia? (Hint: The Media Are a Hazard to Public Health)

Trevor Butterworth, Huffington Post
Take several critics of the way the FDA ensures the safety of drugs, rush a flawed study into print, characterize the results as catastrophic, rope in drug regulation warriors on Capitol Hill, rant about the evils of Big Pharma, talk to a credulous, statistically-illiterate media, and voila - you have Vioxx II, [...]

Avandia Vote a Rebuke to Media Alarmism

Trevor Butterworth
A Food and Drug Administration advisory panel recommended in a 22 to 1 to one vote that the diabetes drug Avandia remain on the market, with additional warnings about cardiac risk, but not the most extreme drug warning – a black box – in the FDA arsenal.
The recommendation, which is non-binding but almost certain [...]

New York Times Cherry Picks Data, Sources to Smear Avandia in Advance of FDA Hearing

Trevor Butterworth
The line between the New York Times editorial page, which has been highly critical of the FDA’s handling of the potential risk from the diabetes drug Avandia, and the health news pages appears to have disappeared in the Times’ coverage of the forthcoming FDA hearings on the drug… more
Originally published July 27, 2007